RTA 404 is an AIM optimized for use in central nervous system indications

RTA 404 – AIM for Autoimmune and Neurological Diseases

RTA 404 is an orally available Antioxidant Inflammation Modulator (AIM) that has been shown to cross the blood-brain barrier and achieve high concentrations in the central nervous system tissue following oral dosing. Like Reata’s other AIMs, it promotes the resolution of innate and adaptive immune-mediated inflammation by restoring redox homeostasis in inflamed tissues. It is a potent inducer of the antioxidant transcription factor Nrf2 and inhibitor of the pro-oxidant/pro-inflammatory transcription factors NF-κB and the STATs. These biological pathways are implicated in a wide variety of diseases, including autoimmune conditions and several neurodegenerative diseases.

Multiple Sclerosis Program
RTA 404 has shown outstanding activity in a number of validated animal models of multiple sclerosis. A publication detailing results of these studies is pending. Based on the activity seen in these models, Reata has moved RTA 404 into clinical candidate status. Upon completion of requisite toxicology studies, Reata plans to file an IND application to study RTA 404 in clinical studies for multiple sclerosis at the end of 2008.

Neurodegenerative Disease Program
The mechanism of action of RTA 404 and other AIMs has been implicated in a number of major neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Preclinical studies in these indications are underway in the laboratories of leading neurodegenerative disease researchers. Pending results of these studies, Reata may pursue a clinical development program of RTA 404 for additional neurological disease indications.